{
  "gene": "EGFR",
  "variant": "L858R",
  "classification": "Oncogenic",
  "highest_level_of_evidence": "Level 1",
  "recommended_therapies": ["Osimertinib", "Afatinib", "Gefitinib"],
  "summary": "EGFR L858R is a classic activating mutation in lung adenocarcinoma with multiple FDA-approved EGFR inhibitors."
}